How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Optilume for treating recurrent bulbar urethral strictures

Closed for comments This consultation ended on at   Request commenting lead permission

2 The technology

Technology

2.1 Optilume is a urethral balloon coated with paclitaxel (3.5 microgram/mm2). It is indicated for managing urethral stricture disease in adults. It is designed to be used as a dilation balloon for a urethral stricture that is 3 cm or less in length.

2.2 Optilume is available in 6 sizes (3 cm and 5 cm length versions, both in 3 different diameters). It is passed over a guidewire under direct vision with or without fluoroscopy, and positioned along the length of the stricture The balloon is then inflated with a provided pressure inflation device, using saline or water. The inflated device is then kept in place for a minimum of 5 minutes to dilate the urethral stricture and allow uptake of paclitaxel.

2.3 Optilume urethral drug coated balloon received a CE mark in September 2020 as a class 3 medical device.

Care pathway

2.4 Current treatment options for recurrent bulbar urethral strictures include endoscopic procedures, urethral dilatation, direct visual internal urethrotomy and urethroplasty. The choice of treatment is considered by a multidisciplinary team and is dependent on patient and clinician choice, and clinician expertise. People having urethroplasty in the UK have often had several previous endoscopic procedures.

2.5 Optilume is intended to be an additional option for treating recurrent strictures that could delay or prevent the need for the more invasive urethroplasty surgery.

Innovative aspects

2.6 Optilume combines balloon dilation of the urethra to widen the stricture with paclitaxel delivered to the tissue of the stricture. The aim of the paclitaxel is to prevent new tissue growth and reduce scar formation.

Intended use

2.7 Optilume is intended as a second-line treatment for urethral strictures in people who have had at least 1 previous endoscopic procedure that has failed. The technology is used by trained consultants in urology, urology trainees and urology nurse specialists. It can be done using local anaesthesia as a day case or in an outpatient setting.

Costs

2.8 Optilume is a single use device and costs £1,350 per unit (excluding VAT). More details about Optilume are available on the company's website.